Literature DB >> 9988230

galectin-1 and galectin-3 expression in human bladder transitional-cell carcinomas.

L Cindolo1, G Benvenuto, P Salvatore, R Pero, G Salvatore, V Mirone, D Prezioso, V Altieri, C B Bruni, L Chiariotti.   

Abstract

Galectin-1 and galectin-3 are galactoside-binding proteins involved in different steps of tumor progression and potential targets for therapy. We have investigated the expression of these galectins in 38 human bladder transitional-cell carcinomas of different histological grade and clinical stage and in 5 normal urothelium samples. Galectin-1 mRNA levels were highly increased in most high-grade tumors compared with normal bladder or low-grade tumors. Western blot and immuno-histochemical analysis of normal and neoplastic tissues revealed a higher content of galectin-1 in tumors. Galectin-3 mRNA levels were also increased in most tumors compared with normal urothelium, but levels were comparable among tumors of different histological grade.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9988230     DOI: 10.1002/(sici)1097-0215(19990219)84:1<39::aid-ijc8>3.0.co;2-e

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  32 in total

Review 1.  Expression of galectins in cancer: a critical review.

Authors:  Frédéric van den Brûle; Stèphane Califice; Vincent Castronovo
Journal:  Glycoconj J       Date:  2002       Impact factor: 2.916

Review 2.  Galectin genes: regulation of expression.

Authors:  Lorenzo Chiariotti; Paola Salvatore; Rodolfo Frunzio; Carmelo B Bruni
Journal:  Glycoconj J       Date:  2002       Impact factor: 2.916

3.  CD24 and galectin-1 expressions in gastric adenocarcinoma and clinicopathologic significance.

Authors:  Sibel Bektas; Burak Bahadir; Bulent Hamdi Ucan; Sukru Oguz Ozdamar
Journal:  Pathol Oncol Res       Date:  2010-02-23       Impact factor: 3.201

Review 4.  Galectins in cancer: carcinogenesis, diagnosis and therapy.

Authors:  Ali Hasan Ebrahim; Zainab Alalawi; Leonardo Mirandola; Rahman Rakhshanda; Scott Dahlbeck; Diane Nguyen; Marjorie Jenkins; Fabio Grizzi; Everardo Cobos; Jose A Figueroa; Maurizio Chiriva-Internati
Journal:  Ann Transl Med       Date:  2014-09

5.  [Galectin expression in urological cancer. Diagnostic, prognostic and therapeutic potential].

Authors:  S Waalkes; A S Merseburger; A Simon; J Serth; M A Kuczyk
Journal:  Urologe A       Date:  2010-03       Impact factor: 0.639

6.  Galectin-1 and its involvement in hepatocellular carcinoma aggressiveness.

Authors:  Daniela Spano; Roberta Russo; Vittorio Di Maso; Natalia Rosso; Luigi M Terracciano; Massimo Roncalli; Luigi Tornillo; Mario Capasso; Claudio Tiribelli; Achille Iolascon
Journal:  Mol Med       Date:  2009-12-21       Impact factor: 6.354

7.  Radiation-induced galectin-1 by endothelial cells: a promising molecular target for preferential drug delivery to the tumor vasculature.

Authors:  Meenakshi Upreti; Azemat Jamshidi-Parsian; Scott Apana; Marc Berridge; Daniel A Fologea; Nathan A Koonce; Ralph L Henry; Robert J Griffin
Journal:  J Mol Med (Berl)       Date:  2012-10-23       Impact factor: 4.599

Review 8.  Glycosylation in bladder cancer.

Authors:  Chikara Ohyama
Journal:  Int J Clin Oncol       Date:  2008-08-15       Impact factor: 3.402

9.  Loss of galectin-3 expression correlates with clear cell renal carcinoma progression and reduced survival.

Authors:  Axel S Merseburger; Mario W Kramer; Jörg Hennenlotter; Jürgen Serth; Stephan Kruck; Alfredo Gracia; Arnulf Stenzl; Markus A Kuczyk
Journal:  World J Urol       Date:  2008-07-02       Impact factor: 4.226

10.  Galectin-3 as a potential therapeutic target in tumors arising from malignant endothelia.

Authors:  Kim D Johnson; Olga V Glinskii; Valeri V Mossine; James R Turk; Thomas P Mawhinney; Douglas C Anthony; Carolyn J Henry; Virginia H Huxley; Gennadi V Glinsky; Kenneth J Pienta; Avraham Raz; Vladislav V Glinsky
Journal:  Neoplasia       Date:  2007-08       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.